CD38 and plasma cell myeloma: The most recently FDA approved CAR T-cell therapy, in February 2022, is ciltacabtagene autoleucel (CARVYKTITM) from Janssen Biotech, Inc. This drug was approved for the treatment of r/r multiple myeloma post four or more prior lines of therapy including an anti-CD38 monoclonal antibody, an immunomodulatory agent (IMiD), and a proteosome inhibitor (PI).